Polymorphisms in Key Genes of Glycolytic Pathway: Influence on Radiosensitivity in Nasopharyngeal Carcinoma

NCT02481089 | Unknown

• 1 other identifier: warburg snp
• Study Type: observational
• Target: 600
• Locations: 1 country
• Sites: 1

Brief Summary

Warburg effect is an important feature of tumors,and genetic variation is one of the main factors of individual differences to radiotherapy treatment response for nasopharyngeal carcinoma(NPC). Through the previous work investigators found that the p53 codon72 (Pro/Arg) was related to the prognosis of NPC; Using the method of proteomics, investigators discovered glycolysis related gene such as PGK1, ALDOA，was associated with radiosensitivity.Thus,with all the previous work,investigators hypothesize that the key gene polymorphisms in glycolytic pathway, such as p53 , influence the glycolytic pathway,which leads to differences in radiosensitivity of NPC. This projects will include 600 cases of patients with NPC to detect common glycolytic key genes polymorphisms. Besides,investigators correlate these factors with their radiosensitivity and prognosis.Then, prediction model will be established, and validation of the prediction model will be done. Using enzyme-labeling instrument ，comet assay and clonogenic assay，cytological experiments will further investigate the influence of key gene polymorphisms on the glycolysis efficiency and mechanism of radiation sensitivity.Thus,investigators could provide theoretical basis of individualized treatment for NPC.

Conditions

Nasopharyngeal Carcinoma; Single Nucleotide Polymorphisms; Radiosensitivity

Outcome Measures

Primary Outcomes (1)

• progression free survival

  up to 60 months

Study Arms (1)

training group

Other: validation group

Interventions

validation group OTHER

training group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

npc patients who can tolerable and agree for IMRT and concurrent chemotherapy

You may qualify if:

• pathological identified NPC
• KPS≥70
• tolerable and agree for IMRT and concurrent chemotherapy
• without severe other diseases
• informed consent

You may not qualify if:

• reject treatment
• cannot tolerate the treatment
• distant metastasis before treatment

Sponsors & Collaborators

• Hunan Province Tumor Hospital: lead

Study Sites (1)

Hunan province tumor pospital

Changsha, Hunan, 410000, China

RECRUITING

MeSH Terms

Conditions

Nasopharyngeal Carcinoma

Condition Hierarchy (Ancestors)

Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Nasopharyngeal Neoplasms; Pharyngeal Neoplasms; Otorhinolaryngologic Neoplasms; Head and Neck Neoplasms; Neoplasms by Site; Nasopharyngeal Diseases; Pharyngeal Diseases; Stomatognathic Diseases; Otorhinolaryngologic Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: chief of thoracic radiation oncology department

Study Record Dates

• First Submitted: June 2, 2015
• First Posted: June 25, 2015
• Study Start: June 1, 2015
• Primary Completion: December 1, 2018
• Last Updated: February 19, 2016

Record last verified: 2016-02

Locations

CN (1)